VISTARIL (hydroxyzine hydrochloride) by Pfizer is clinical pharmacology hydroxyzine hydrochloride is unrelated chemically to the phenothiazines, reserpine, meprobamate or the benzodiazepines. Approved for anxiety. First approved in 1957.
Drug data last refreshed 5h ago · AI intelligence enriched 3w ago
VISTARIL (hydroxyzine hydrochloride) is a small-molecule anxiolytic approved in 1957 that acts through suppression of subcortical CNS activity rather than cortical depression. It treats anxiety and exhibits bronchodilator, antihistaminic, analgesic, and antiemetic properties with clinical effects noted 15-30 minutes post-administration.
Declining revenue base with minimal Part D claims signals small team sizing and limited growth opportunities for commercial expansion.
CLINICAL PHARMACOLOGY Hydroxyzine hydrochloride is unrelated chemically to the phenothiazines, reserpine, meprobamate or the benzodiazepines. Hydroxyzine is not a cortical depressant, but its action may be due to a suppression of activity in certain key regions of the subcortical area of the…
Does Preventive Analgesia Improve the Outcome of Demerol-Vistaril Procedural Sedations in Pediatric Dentistry
Worked on VISTARIL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moVISTARIL offers limited career growth due to legacy status, minimal linked job openings, and approaching loss of exclusivity; roles focus on brand defense and compliance rather than innovation. Career progression likely requires movement to higher-growth Pfizer assets or competitive products.